Quantitative Concept – Page 15

Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases

4 months ago talkbio0Tagged Capital, Chronic Immune-Mediated Diseases, engagers, immune reset, innovations, Monograph, NEA, Norwest, Ouro Medicines, Partner in relationship, SmithKline Beecham, T-Lymphocyte, TPG, venture

Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

4 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG

Light Horse Therapeutics Secures $62M Series A Funding and Partners with Novartis for Cancer Therapies

4 months ago talkbio0Tagged Cancer Therapeutic Procedure, Funding, genetic editing, Light Horse, Novartis, Precision - temporal, Series, small molecule therapeutics

Light Horse Therapeutics, Novartis, Series A funding, cancer therapies, small molecule therapeutics, precision genetic editing platform

Revival of Dormant Antipsychotic Class: LB Pharma’s Phase II Success with LB-102

4 months ago talkbio0Tagged Antipsychotic Agents, benzamide, LB-102, Pharma, Phase 2 Clinical Trials, Pounds, Schizophrenia

LB Pharma, LB-102, Antipsychotic drugs, Schizophrenia treatment, Phase II clinical trials, Benzamide antipsychotics

Novo Nordisk and Variant Bio Collaborate on Metabolic Disease Research, Focusing on Diverse Populations

4 months ago talkbio0Tagged benefit-sharing program, Bio, Diversity, Genetic Research, geographic population, Metabolic Diseases, Nordisk, Variant, VB-Inference platform

Novo Nordisk, Variant Bio, Metabolic disease, Genetic research, Diverse populations, VB-Inference platform, Benefit-sharing program

Orbis Medicines Secures €90 Million Series A Funding to Revolutionize Oral Macrocycle Drug Discovery

4 months ago talkbio0Tagged biologic drug alternatives, Funding, nCycles, Oral Macrocycle, Orbis Medicines, pharmaceutical innovation, Series

Orbis Medicines, Series A funding, oral macrocycle drugs, nCycles, biologic drug alternatives, pharmaceutical innovation

Orbis Kicks Off 2025 with €90M Series A Funding in Fierce Biotech Fundraising Tracker

4 months ago talkbio0Tagged biotech, Biotech Fundraising Tracker, Biotech Investments, Capital, Fierce, Funding, funding rounds, Orbis, Series, venture

Fierce Biotech Fundraising Tracker 2025, Orbis Series A Funding, Biotech Venture Capital, 2025 Biotech Investments, Series A Funding Rounds

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

4 months ago talkbio0Tagged agonists, aspects of adverse effects, Diabetes Mellitus, Non-Insulin-Dependent, Employer, Endorsements, Famous Persons, Financial cost, Glucagon-Like Peptide 1, Health Planning, Long-term Safety, Weight Loss

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans

HUTCHMED Divests 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million to Focus on Core Oncology Pipeline

4 months ago talkbio0Tagged antibody-targeted therapy, ATTCs, HUTCHMED, Immunostimulating conjugate (antigen), Oncology Pipeline, profitability, Shanghai, Strategic Focus

HUTCHMED, Shanghai Hutchison Pharmaceuticals, divestment, oncology pipeline, antibody-targeted therapy conjugates (ATTCs), strategic focus, profitability.

GSK’s Zejula-Jemperli Combination Achieves Primary Endpoint in Ovarian Cancer Trial, Falls Short on Overall Survival

4 months ago talkbio0Tagged FIRST trial, Jemperli, ovarian neoplasm, Progression-Free Survival, SmithKline Beecham, Survival, Zejula

GSK, Zejula, Jemperli, ovarian cancer, FIRST trial, progression-free survival, overall survival